Sclerosing cholangitis

Sclerosing cholangitis (SCC) is a chronic disease characterized by inflammation and narrowing of the bile ducts. This leads to damage to the biliary mucosa and subsequent formation of fibrous tissue, which in turn leads to obstruction of bile flow. SCC is most often associated with autoimmune diseases such as chronic active hepatitis and ulcerative colitis and manifests itself with the development of cholestasis, liver failure and, ultimately, cirrhosis. Epidemiological data indicate a high incidence rate in men aged 30 to 60 years, which highlights the need for a more in-depth study of the factors contributing to the development of this disease.

History of the disease and interesting historical facts

The history of sclerosing cholangitis goes back several decades. The first descriptions of the disease belonged to doctors in the middle of the 20th century, when cases of combination of cholangitis with inflammatory bowel diseases began to be recorded. In 1970, the American hepatologist Dr. Kerry proposed the term "sclerosing cholangitis", which has become established in medical practice. Interestingly, in the first years of observation of this disease, the connection with genetic factors and autoimmune processes was not established, however, later studies began to reveal a correlation between SCC and a number of hereditary syndromes.

Epidemiology

Sclerosing cholangitis occurs with a frequency of 6-16 cases per 100,000 population per year. There is a gender predisposition to this disease: men are more often affected than women (ratio 2:1). SCC is most common among people suffering from chronic inflammatory bowel diseases, especially ulcerative colitis, in whom the risk of developing the disease increases to 15%. According to epidemiological studies, in a population with genetic predispositions, the frequency of SCC can reach 40%.

Genetic predisposition to this disease

Studies have shown that there is a genetic predisposition to sclerosing cholangitis. In particular, associations with certain HLA class II alleles have been noted, including HLA-DR2 and HLA-DR3. Genes responsible for regulatory processes in the immune system, such as IL-12 and TNF-α, are also known to be involved, confirming the autoimmune nature of the disease. Analysis of genetic markers in related groups has shown that the presence of SCC cases increases the risk of the disease in close relatives up to three times. However, the exact nature of the genetic mutations that contribute to the development of SCC is not fully understood.

Risk factors for the development of this disease

Among the risk factors that contribute to the development of sclerosing cholangitis are:

• The presence of chronic inflammatory bowel disease, especially ulcerative colitis;
• History of autoimmune diseases (eg, primary biliary cholangitis);
• Smoking and alcohol abuse;
• Family history of SCC cases;
• Environmental factors such as exposure to toxic substances and chemical compounds.

Environmental factors also play an important role in the pathogenesis of the disease. For example, exposure to pesticides and certain industrial chemicals may increase the risk of developing SCC.

Diagnosis of this disease

Diagnosis of sclerosing cholangitis is based on a comprehensive approach, which includes the following stages:

• The main symptoms are itchy skin, jaundice, headaches, fatigue and elevated liver enzymes;
• Laboratory tests: determination of alkaline phosphatase levels, as well as tests for the presence of antimitochondrial antibodies;
• Radiological examinations: MRI and CT cholangiopancreatography for visualization of the biliary tract;
• Other types of diagnostics: endoscopic ultrasound examination and liver biopsy to exclude other liver diseases;
• Differential diagnosis: it is necessary to exclude primary biliary cholangitis, viral hepatitis and bile duct tumors.

Early diagnosis is key to successful treatment and control of the disease.

Treatment

Treatment of sclerosing cholangitis includes both conservative and surgical methods:

• General treatment: lifestyle changes, low-calorie diet and abstinence from alcohol;
• Pharmacological treatment: use of ursodeoxycholic acid, which helps improve liver function and reduce bilirubin levels;
• Surgical treatment: In cases of bile duct obstruction, stent placement or surgery may be required;
• Other treatments: Immunosuppressive therapy, including corticosteroids, may be useful when combined with other autoimmune diseases.

It is important that each treatment is selected individually depending on the stage of the disease and the patient's condition.

List of medications used to treat this disease

The main drugs used to treat sclerosing cholangitis include:

• Ursodeoxycholic acid
• Prednisolone;
• Azathioprine;
• Mycophenolate mofetil;
• Routine.

These drugs help reduce the manifestations of the disease, minimize side effects and improve the quality of life of patients.

Disease monitoring

Monitoring of patients with sclerosing cholangitis includes regular follow-up examinations aimed at assessing liver function and bilirubin levels:

• Control stages: regular visits to a gastroenterologist and laboratory tests every 3-6 months;
• Prognosis: With early diagnosis, the prognosis can be favorable, although in most cases the disease progresses;
• Complications: complications such as liver failure, infectious processes and bile duct cancer are possible.

However, with timely treatment, the quality of life of patients can be significantly improved.

Age-related features of the disease

Sclerosing cholangitis is most often diagnosed in adults, but cases of the disease may manifest in childhood and adolescence. In older patients, the disease may develop with less pronounced symptoms, which makes diagnosis more difficult. In children, SCC may be combined with other autoimmune diseases and metabolic disorders, which requires a special approach to treatment and monitoring.

Questions and Answers

• What is sclerosing cholangitis? Sclerosing cholangitis is a chronic inflammatory disease of the bile ducts, leading to their narrowing and damage to the liver.
• What are the main symptoms of the disease? The main symptoms include jaundice, itchy skin, increased fatigue and increased liver enzymes.
• How is sclerosing cholangitis diagnosed? Diagnosis involves analysis of clinical symptoms, laboratory tests, radiological examinations and sometimes liver biopsy.
• How is this disease treated? Treatment can be conservative (pharmacological) or surgical, depending on the stage of the disease and the general condition of the patient.
• What is the prognosis for patients with sclerosing cholangitis? The prognosis depends on the stage of the disease and the effectiveness of treatment, but many patients can live with the disease for a significant time with proper treatment.